Dataset Information

Unraveling linc00645: A Wnt-regulated lncRNA driving epithelial-mesenchymal transition through the linc00645/miR-452-5p/vimentin axis in triple-negative breast cancer

ABSTRACT: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis and high recurrence rates. Wnt signaling plays a critical role in the pathogenesis of TNBC, with aberrant activation of this pathway observed in many cases. Emerging evidence suggests that long non-coding RNAs (lncRNAs) may modulate key signaling pathways, including Wnt signaling, in TNBC. In this study, we investigated the interplay between lncRNAs and Wnt pathway activation in TNBC. RNA-Seq analysis comparing Wnt-positive and Wnt-negative cell lines derived from MDA-MB-231 identified linc00645 as a highly upregulated lncRNA in Wnt-activated cells. Further gene ontology analysis revealed that the differentially expressed lncRNAs, including linc00645, were enriched in pathways related to epithelial-to-mesenchymal transition (EMT), a key process in cancer metastasis. To validate these findings, recombinant human Wnt3A was used to activate the Wnt pathway in MDA-MB-231 cells. RT-qPCR confirmed the upregulation of linc00645 in Wnt-activated cells. Functional studies demonstrated that knockdown of linc00645 led to a significant reduction in cell proliferation and migration in TNBC cells, suggesting its oncogenic role. Moreover, mechanistic investigations revealed that linc00645 directly interacts with miR-452-5p, leading to the downregulation of this microRNA and the upregulation of the mesenchymal marker vimentin, further promoting EMT. These findings suggest that linc00645 functions as an oncogenic lncRNA in Wnt-activated TNBC by regulating the linc00645/miR-452-5p/vimentin signaling axis. Targeting this axis could represent a novel therapeutic strategy for treating TNBC. This study highlights the potential of linc00645 as a promising target for interventions aimed at inhibiting TNBC progression.

ORGANISM(S): Homo sapiens

PROVIDER: GSE320213 | GEO | 2026/02/23

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Tumor infiltrating lymphocytes (TILs) play a critical role in modulating the immunoediting features in certain malignancies like triple negative breast cancer (TNBC). Nevertheless, much is still unknown concerning the specific responses of tumors when challenged by lymphocyte infiltration. Based on this void, we conducted a immuno-phenotype comparison using mRNA sequencing between the TNBC cell line MDA-MB-231 and the luminal breast cancer cell line MCF7 after both were co-cultured with activated human T-cells. We found that, though the cytokine-induced immune signature of the two cell lines was similar, MDA-MD-231 cells were able to transcribe IDO1 at a significantly higher level than MCF7 cells. Though no differences occurred in upstream JAK/STAT1 signaling or IDO1 mRNA stability between the two cell lines, stimulation with IFNÎ³ was able to differentially induce IDO protein expression and enzymatic activity in ER- cell lines compared to ER+ cell lines. Further experiments show that 5-aza-deoxycytidine treatment was able to reverse suppression of IDO1 expression in MCF7 cells, suggesting DNA methylation as a potential determinant in IDO1 induction. By analyzing TCGA breast cancer datasets, we discovered subtype-specific mRNA and promoter methylation differences in IDO1, with TNBC/basal subtypes exhibiting lower methylation/higher expression and ER+/luminal subtypes exhibiting higher methylation/lower expression. We confirmed this trend of IDO1 methylation by bisulfite pyrosequencing breast cancer cell lines and an independent cohort of primary breast tumors. Taken together, these findings suggest that IDO1 methylation regulates anti-immune responses in breast cancer subtypes and could be used as a predictive biomarker for IDO inhibitor-based immunotherapy. To determine the immunomodulatory effects of cytokines secreted by activated human T-cells on breast cancer cells, we performed RNAseq analysis in MCF7 and MDA-MB-231 cells, after co-culturing them with normal PBMCs activated with anti-CD3/CD28 antibodies in a contact-independent manner. MDA-MB-231 or MCF7 cells were co-cultured with PBMCs alone or the conditioned-media or a combination of both for 24 hrs, and then total RNA was harvest for RNA-seq analysis.

Project description:Background: Triple-negative breast cancer (TNBC) urgently needs effective therapies due to limited targeted options and unfavorable outcomes. We investigated Trichosanthes kirilowii Maxim formula granules (TKM) using integrated network pharmacology, metabolomics, and molecular pharmacology to clarify potential multi-target mechanisms relevant to TNBC.Methods: Liquid chromatography coupled with mass spectrometry was employed to identify the components of TKM formula granules. Network pharmacology-based prediction was used to uncover potential mechanisms by which TKM counteracts TNBC. Potential targets were identified, and pathway enrichment analysis was performed. Subsequently, TNBC cells and 4T1 tumor-bearing mice were used to verify the molecular mechanisms of TKM.Results: We identified 151 active compounds in TKM. Through network pharmacology analysis, 214 TNBC-related targets were found, with 28 core targets, including cell cycle and apoptosis regulators MYC, TP53, AKT1, CCND1, CASP3, PIK3CA, BCL2L1, and CDC42. The compound-target-pathway-disease network showed that schisandrin binds to many treatment targets with satisfactory docking performance, especially for MYC and AKT1. Experimentally, TKM was found to significantly promote apoptosis and induce G2/M-phase cell-cycle arrest in MDA-MB-231 cells. Western blot analysis showed that TKM suppressed PI3K/AKT and Wnt/β-catenin signaling pathways. Surface plasmon resonance experiment revealed that schisandrin binds to recombinant AKT1 with an equilibrium dissociation constant (K_D) of 0.1525 mM. According to untargeted metabolomics results, TKM can regulate amino acid, glycine, serine, and threonine metabolism, mineral absorption, protein digestion and absorption, central carbon metabolism, and arginine biosynthesis to exert therapeutic effects on TNBC. All findings were consistent with predicted targets and pathways.Conclusion: This study comprehensively explores the multi-target mechanisms of TKM against TNBC using network pharmacology, molecular pharmacology, and metabolomics approaches. These findings provide a foundation for future mechanistic investigations and may support the further preclinical development of TKM-based strategies for TNBC.

Dataset Information

Unraveling linc00645: A Wnt-regulated lncRNA driving epithelial-mesenchymal transition through the linc00645/miR-452-5p/vimentin axis in triple-negative breast cancer

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets